Pharmaceutical

Alexion Pharmaceuticals

$159.37
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.87 (+1.18%) Today
-$0.36 (-0.23%) As of 11:49 AM UTC after-hours

Why Robinhood?

You can buy or sell ALXN and other stocks, options, and ETFs commission-free!

About ALXN

Alexion Pharmaceuticals, Inc. Common Stock, also called Alexion Pharmaceuticals, is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Boston, MA. The listed name for ALXN is Alexion Pharmaceuticals, Inc. Common Stock.

CEO
Ludwig N. Hantson
Employees
3,082
Headquarters
Boston, Massachusetts
Founded
1992
Market Cap
34.91B
Price-Earnings Ratio
37.33
Dividend Yield
—
Average Volume
3.74M
High Today
$160.33
Low Today
$158.01
Open Price
$158.35
Volume
2.79M
52 Week High
$160.33
52 Week Low
$72.67

Collections

ALXN Earnings

$0.00
$1.08
$2.16
$3.24
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 4, Pre-Market

You May Also Like

GS-D
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure